TaxTMI Login
AI OCR ✕Convert scanned orders, printed notices, PDFs and images into clean, searchable, editable text within seconds. Starting at 2 Credits/page
Try Now →Just a moment...
AI OCR ✕Convert scanned orders, printed notices, PDFs and images into clean, searchable, editable text within seconds. Starting at 2 Credits/page
Try Now →
Press 'Enter' to add multiple search terms. Rules for Better Search
Use comma for multiple locations.
---------------- For section wise search only -----------------
Accuracy Level ~ 90%
of 
Press 'Enter' after typing page number.
of Press 'Enter' after typing page number.
No Folders have been created
Are you sure you want to delete "My most important" ?
NOTE:
of Press 'Enter' after typing page number.
of Press 'Enter' after typing page number.
All Case Laws
of Press 'Enter' after typing page number.
of Press 'Enter' after typing page number.
All Case Laws
Note
Bookmark
Share
Don't have an account? Register Here
of Press 'Enter' after typing page number.
Issues: (i) Whether monoclonal antibodies used as blood-grouping reagents were classifiable under Heading 30.05 or Heading 30.02 of the Central Excise Tariff Act, 1985; (ii) whether pregnancy test kits based on anti-hCG antibodies were classifiable under Heading 30.02 or Heading 38.22; (iii) whether syphilis RPR and salmonella antigens were classifiable under Heading 38.22; and (iv) whether the extended period of limitation, penalty and interest were correctly invoked, including the penalty on the Managing Director.
Issue (i): Whether monoclonal antibodies used as blood-grouping reagents were classifiable under Heading 30.05 or Heading 30.02 of the Central Excise Tariff Act, 1985
Analysis: The products were marketed and labelled by the assessee as blood-grouping and blood-typing reagents, meant only for in-vitro and laboratory use and not for medicinal use. The Court applied the scheme of Chapter 30, the specific entry for blood-grouping reagents in Note 3(e), and the common parlance test. It held that the technical character of the goods could not displace the specific tariff description under which they were known to users. Heading 30.02 was found inapplicable on the facts.
Conclusion: The classification under Heading 30.05 was upheld and the claim under Heading 30.02 was rejected, against the assessee.
Issue (ii): Whether pregnancy test kits based on anti-hCG antibodies were classifiable under Heading 30.02 or Heading 38.22
Analysis: The anti-hCG antibodies used in the kits were found to be derived from antisera. The Court held that antisera under Heading 30.02 include purified and refined forms and may also be used for diagnostic in-vitro tests. Since Heading 38.22 is residual and excludes diagnostic or laboratory reagents of Chapter 30, the pregnancy test kits were held to fall within Heading 30.02 and not Heading 38.22.
Conclusion: The classification under Heading 38.22 was set aside and the kits were held classifiable under Heading 30.02, in favour of the assessee.
Issue (iii): Whether syphilis RPR and salmonella antigens were classifiable under Heading 38.22
Analysis: The assessee failed to substantiate its claim that these products were covered by Heading 30.02. The labels and literature showed that they were laboratory diagnostic products, but not material sufficient to establish classification under Chapter 30 was produced. On the record, the Court found no reason to interfere with the adjudicating authority's classification.
Conclusion: The classification under Heading 38.22 was upheld, against the assessee.
Issue (iv): Whether the extended period of limitation, penalty and interest were correctly invoked, including the penalty on the Managing Director
Analysis: The Court held that suppression and misdeclaration were established because the assessee did not make full disclosure of the products' nature, manufacture and clearances, and the Department became aware of the necessary facts only later. The extended period was therefore sustained for the relevant products. However, the quantum of duty and penalty required re-quantification, the penalty could not operate for the period before 28-9-1996, and no adequate evidence was found to sustain the personal penalty against the Managing Director under Rule 209A.
Conclusion: The extended period and interest were sustained, the composite penalty on the assessee was set aside for redetermination, and the personal penalty on the Managing Director was set aside, partly in favour of the assessee.
Final Conclusion: The appeals were disposed of by sustaining the revenue's classification only in part, granting relief on pregnancy test kits and the personal penalty, and remitting the duty and penalty quantification for reconsideration in accordance with law.
TaxTMI 
TaxTMI 
